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Summary The kinetics of dexamethasone-induced death of CCRF CEM clone C7A human lymphoblastic
leukaemia cells was determined with respect to changes in the expression of the c-myc protein. Cell death was
characterised as being by apoptosis: cells with an intact plasma membrane had condensed chromatin and were
characterised as having approximately 300 kbp fragments when DNA integrity was analysed by pulsed-field
electrophoresis. Onset of apoptosis required a minimum of 36 h exposure to 5AIM dexamethasone; before this
time no apoptotic cells were observed. This 36 h incubation period appeared to be necessary to prime the cells
for subsequent death by apoptosis. In the continued presence of dexamethasone the percentage of apoptotic
cells increased to 60% apoptotic cells by 54 h. Investigation of changes in c-myc protein showed that it was
undetectable after 12 h of incubation with dexamethasone, although cells were not committed to die at this
time. Cells were treated with dexamethasone for 54 h and for various pulsed periods with a non-toxic
concentration ofcycloheximide (200 nM). When cycloheximide was present during the first 36 h priming period
of dexamethasone treatment, there was an immediate loss of c-myc protein and apoptosis at 54 h was
completely inhibited. In contrast, there was no inhibition of apoptosis when dexamethasone-treated cells were
incubated with an 18 h pulse of cycloheximide added after 36 h. Cells exposed to dexamethasone for 36 h
('primed') were given various periods of dexamethasone-free incubation before readdition of dexamethasone
for a further 18 h. The longer the cells were free of drug after priming, the less susceptible they became to
apoptosis, suggesting a slow decay of their 'memory' of the initial 36 h period of exposure. Cycloheximide
inhibited the decay of this memory. Removal of dexamethasone after a 36 h exposure was characterised by a
subsequent 24 h suppression of c-myc protein expression. Despite this, 90% of cells became refractory to
apoptosis before the reappearance of c-myc protein. The evidence does not support the hypothesis that
changes in c-myc expression are required for the engagement of apoptosis of CEM cells.
The induction of apoptosis in lymphocytes and lymphoblas-
toid leukaemic cell lines by glucocorticoids provides a useful
model for the study of the changes in gene expression that
may initiate their demise (Owens & Cohen, 1992). In the
human T-lymphocytic cell line CCRF CEM, evidence to date
suggests that suppression of gene expression is required for
the initiation of apoptosis (Yuh & Thompson, 1989;
Nazareth et al., 1991). Congruent with the idea that trans-
criptional suppression is required, Yuh & Thompson (1989)
reported that an early event in the dexamethasone-induced
cell death of CCRF CEM clone C7A cells was a decrease in
the transcription of the c-myc oncogene, itself postulated to
be a transcriptional regulator (Cole, 1991; Eilers et al., 1991).
Although levels of cellular c-myc RNA fell by 12 h, the cells
did not die at this time but required another 24 h of dexa-
methasone exposure before cell death was observed (Yuh &
Thompson, 1989). Recently, it was reported that transient
transfection of these cells with a number of c-myc constructs
inhibited dexamethasone-induced apoptosis (Thulasi et al.,
1993). This finding contrasts with recent findings that
deregulated expression of c-myc in mesenchymal and myeloid
cells is a potent inducer of apoptosis (Askew et al., 1991;
Evan et al., 1992). Furthermore, the hypothesis that tran-
scriptional suppression by dexamethasone is required to
initiate a programmed cell death, and specifically the c-myc
gene, had to be reconciled with the finding that CCRF CEM
apoptotic cell death was partially inhibited by cycloheximide,
an inhibitor of protein synthesis (Bansal et al., 1991). This
supports the idea that some element of protein synthesis may
be required for cell death, presumably after transcriptional
activation by the glucocorticoid.
We have further characterised the kinetics of cell death of
CCRF CEM clone C7A cells, which is by apoptosis, with
respect to changes in the expression of the product of the
c-myc gene. In particular we have shown, using pulsed
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exposures to cycloheximide, that there are distinct periods
during the engagement of apoptosis in which first transcrip-
tional activation and then suppression may occur. Addi-
tionally, cells treated with dexamethasone retain a slowly
decaying 'memory' ofexposure during the period when trans-
criptional activation may be required. However, the kinetics
of decay of this 'memory' does not support the idea that a
change in the expression of the proto-oncogene c-myc is
sufficient for the engagement of apoptosis of CEM cells.
Materials and methods
Materials
All materials were purchased from Sigma (Poole, UK) unless
otherwise stated.
Cell culture
The T-cell lymphoblastic leukaemia cell line CCRF CEM
clone C7A was kindly donated by E. Brad Thompson, The
University of Texas, Galvaston, TX, USA. This
glucocorticoid-sensitive cell line was originally cloned and
characterised by Norman & Thompson (1977) and described
further by Yuh & Thompson (1989). Cells were grown as a
suspension in RPMI-1640 medium (Gibco, Glasgow, UK)
supplemented with 10% heat-inactivated fetal calf serum
(Applied Protein Products, Lewes, Sussex, UK). Cultures
were incubated at 37°C in a humidified atmosphere of 5%
carbon dioxide and discarded after 30 subcultures to prevent
phenotypic drift. The cells had a doubling time of approx-
imately 24 h.
Drug treatment
Cells (2 x 105 ml-') in the logarithmic phase of cell growth
were exposed to various agents for the times noted. Agents
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were dissolved in absolute ethanol,'the final volume of which
was not greater than 0.1% (v/v). Control cultures received
the solvent alone. All experiments were repeated at least
three times.
Measurement ofcell integrity and apoptosis
Cell membrane integrity was measured by the exclusion of a
0.4% solution of trypan blue. Apoptosis was measured by
addition (1:1) of a solution of 10 igml' acridine orange
(Molecular Probes, Eugene, OR, USA) to suspensions of
between 105 and 106 cells ml1'. Apoptotic cells were scored as
described previously; these had condensed chromatin but an
intact plasma membrane that excluded trypan blue (Dive et
al., 1992) (see Figure 1). More than 200 cells were scored on
each occasion and the experiments were repeated at least
three times.
Estimation ofDNA integrity
Standard agarose gel electrophoresis Cells were washed three
time with prewarmed phosphate-buffered saline (PBS) and
centrifuged at 170g for 5 min. A pellet of 106 cells was
resuspended in a lysis buffer of 5% sodium sarkosinate,
200 mM EDTA and 500 mM Tris-HCl, then 20 tlA of a
0.5mgml-l solution of proteinase K was added and the
mixture incubated at 50C for 1 h. A 10 g aliquot of a
0.5 mgml1' solution of RNAse (Boehringer Mannheim, UK)
was added and the incubation continued for 45 min at 50°C.
Finally, 10 il of 1% low melting point agarose (Sea-Plaque,
Sittingbourne, Kent, UK) was added and the mixture
incubated at 70°C for 15 min. Samples were loaded onto a
2% agarose gel and run in Tris-phosphate EDTA (TPE) at
40 V for 2 h. The gel was stained with ethidium bromide and
viewed under ultraviolet light.
Pulsed-field electrophoresis Cells were washed three times
with prewarmed PBS and centrifuged at 170g for 5 min. A
pellet of 106 cells was resuspended in 100ftl of molten 1%
low melting point agarose prepared in PBS, and set into
plugs using a Perspex mould. The plugs were incubated at
50°C for 24 h in 1 ml of L buffer (0.1M EDTA pH 8.0,
0.01 M Tris-Cl pH 7.6, 0.02M sodium chloride) containing
1 mgml-' proteinase K. The plugs were washed twice for 2 h
in L buffer. Prior to electrophoresis the plugs were equilib-
rated in TE (10 mM Tris EDTA, pH 8.0). The plugs were
sealed into a 1.5%.gel with 1% low melting point agarose.
Lambda phage and yeast artificial chromosome fragments
were used as markers ranging from 50 to 1,000 kb. The
electrophoresis was performed for 24 h at 150 V in
0.5 x TAE (40 mM Tris acetate, 1 mM EDTA, pH 8.6) with a
pulse time of 65 s using a Walter II horizontal gel chamber
(Tribotics). The gel was stained with ethidium bromide and
viewed under ultraviolet light.
Western blotting
Proteins from 1 x 105 cells were separated using SDS-PAGE
and electrophoretically transferred to nitrocellulose filter
(Hybond Extra-C, Amersham, UK) by the method of Tobin
et al. (1979). Immunoblotting was performed using the
monoclonal mouse anti-human antibody, CT9, raised to a
peptide from the C-terminal end of the c-myc protein (Evan
et al., 1985). Peroxidase-conjugated secondary antibodies
were incubated with the blots for 1 h before visualising the
proteins by use of an enhanced chemoluminescence system,
according to the manufacturer's instructions (Amersham,
UK). Gels were then stained with Coomassie blue to ensure
that transfer was complete.
Cell cycle analysis byflow cytometry
Cells were washed twice with PBS and 106 cells placed in
500IlI of 0.1% paraformaldehyde in PBS, pH 7.4, containing
0.1% Triton X-100. Cell samples were stained with 20jil of
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Figure 1 a, A photomicrograph of CEM clone C7A cells treated
for 54 h with dexamethasone, stained with I ;Lgml1-' acridine
orange and viewed by confocal microscopy to obtain a rather
sharper image than that from a fluorescent microscope. Apop-
totic cells have condensed chromatin (arrow), often arranged in a
hemilunar crescentic mass at the nuclear margin (CON = con-
trols; DEX = dexamethasone). b, Electrophoresis in agarose of
the DNA from clone C7A cells treated for 54 h with dex-
amethasone showed only a weak classical 'laddering' pattern of
DNA cleaved at approximately 200 bp integers. (M = molecular
weight markers; C = control cells and at 54 h after dex-
amethasone treatment). c, Pulsed-field electrophoresis of DNA
from clone C7A cells treated with dexamethasone for various
times. (C = controls; D = 48 h, E = 54 h and F = 60 h after dex-
amethasone; M = molecular weight markers; Y = yeast artificial
chromosome fragments).
2.5mgml-l propidium iodide for 1-2min prior to flow
cytometric analysis using a Coulter Epics V (Coulter, Luton,
UK). The cytometer was set to excite at 400 mW with the
488 nm line; red fluorescence was collected through a 630-
nm-long bandpass filter. Approximately 2 x 104 cells were
analysed with respect to red fluorescence, at a flow rate of
between 2 and 2.5 x 103 cells s-'. Data were analysed as
single-parameter DNA frequency histograms using in-house
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Results
Morphological and biochemicalfeatures ofCCRF CEM clone
C7A cell apoptosis
Figure la shows the morphological features of 5jtM
dexamethasone-induced apoptosis in clone C7A cells.
Typically, fluorescence microscopy showed that apoptotic
cells contained discrete masses of condensed chromatin while
membrane integrity was maintained at >95% as measured
by the exclusion of trypan blue. With time, membrane inte-
grity was lost and the cells then appeared to be swollen and
necrotic. Morphological analysis allowed quantitative kinetic
estimations of the rate of onset of apoptosis; this type of
analysis has been absent from other studies, in which cell
lysis and loss of membrane integrity have been estimated. In
our hands, the loss of membrane integrity was an event
occurring after the appearance of condensed chromatin.
When the numbers of plasma membrane-intact cells with
morphological features of chromatin condensation was max-
imum (>80%), isolation of DNA from these cells showed
that it had undergone a modest degree of internucleosomal
cleavage typical of apoptosis, presumably after activation of
an endonuclease (Figure lb). Despite intensive efforts only a
very weak 'chromatin ladder' typical of the internucleosomal
cleavage of DNA to 180-200 bp fragments was observed.
However, pulsed-field electrophoresis, which allows the
resolution of larger fragments of DNA, showed the early
appearance of approximately 300 kbp DNA fragments at
times corresponding to the appearance of condensed
chromatin (Figure 1c), although this was accompanied by a
general fragmentation to lower molecular weights. The loss
of the 300 kbp fragment with time and the increase in inten-
sity of the smaller fragments was an event similar to that
observed by us in mesenchymal and epithelial cells undergo-
ing apoptosis (Oberhammer et al., 1993) and in thymocytes
(Brown et al., 1993). This is discussed below.
Kinetics ofdexamethasone-induced apoptosis
Continuous incubation of clone C7A cells with 5iLM dex-
amethasone induced apoptosis with the kinetics shown in
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Figure 2a. Previous experiments by us, using a range of
concentrations of the steroid, had established that over a
72 h period a 5pM concentration of dexamethasone induced
maximal apoptosis with minimal loss of membrane integrity
by 72 h (data not shown). For example, treatment with 1lLM
dexamethasone induced less than 40% apoptosis by 48 h,
whereas this was >55°% with 5;tM dexamethasone. During
the first 36 h of incubation with 51LM dexamethasone, at
which time there were no apoptotic cells, cell numbers in-
creased as shown in Figure 2b, with little change in the rate
of cell division. After 36 h there was no further increase in
cell number in the treated cells and only thereafter did cells
begin to accumulate in the GI phase of the cell cycle (see
below). Removal of the dexamethasone at any time before
36 h did not result in apoptosis above the control levels over
the next 36 h, confirming similar observations by Yuh &
Thompson (1989), who used trypan blue to assess viability.
Continued incubation with dexamethasone after the initial
36 h of exposure resulted in an accumulating amount of
apoptosis over the next 36 h (total exposure 72 h). A 54 h
total drug exposure (36 h + 18 h) was selected as an optimal
time at which to measure significant changes in apoptosis,
since at this time there was minimal loss of membrane inte-
grity with high numbers of apoptotic cells (Figure 2a). We
suggest that the first 36 h of exposure to dexamethasone may
be equivalent to a 'priming' period, after which the cells
became committed to apoptosis on further exposure to the
drug. This idea is supported by data from experiments with
pulsed incubations with cycloheximide, discussed below.
Changes in cell cycle
It has been shown previously that dexamethasone-induced
cell death occurs in the GI phase of the cell cycle of CCRF
CEM cells (Harmon et al., 1979). Analysis of the cell cycle
during the course of drug exposure showed that there was no
change after 24 h of incubation with dexamethasone, with
56.5 ± 3.6% (n = 3, ± s.e.m.) in the GI phase. The propor-
tion of GI phase cells had increased only slightly by 36 h to
62.5%, at which time the cells had completed the 'priming'
phase but had not yet undergone apoptosis. Only thereafter
did the proportion of cells which accumulated in GI rise: by
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Figure 2 a, Kinetics of the onset of cell death in clone C7A cells continuously treated with 5ltM dexamethasone and observed, by
microscopy at each time point, in the presence of either 2jigml-' acridine orange or 0.2% trypan blue. E , trypan blue-positive
cells; _, cells with condensed chromatin ('apoptotic') (means of at least three experiments, ± s.e.m). b, Growth kinetics under
identical conditions to a (s.e.m. <5%, n = 3). c, Representative Western blot of the cellular content, at various times, of c-myc
protein during continuous incubation of clone C7A cells with 5gtM dexamethasone: C = control.666 A.C. WOOD et al.
21.5% to 78% at 48 h and by 25.6% to 82% by 54 h.
Hypodiploid material, representing apoptotic cells, was gated
out from each of these analyses.
Changes in the expression ofc-mycprotein
The changes in cellular levels of the c-myc protein during
incubation with dexamethasone are shown in Figure 2c and
are in good agreement with the estimation of changes in the
cellular amount of c-myc RNA, which fell dramatically after
12 h, as also reported by Yuh & Thompson (1989) under
almost identical conditions, but using 1 gM dexamethasone.
The rapid disappearance of protein reflects the very short
half-life of the c-myc protein (c. 0.5 h) (Waters et al., 1991).
Inhibition ofapoptosis and reduction ofc-mycprotein by
cycloheximide
Cycloheximide (CHX) (178 nM) has been shown to partially
inhibit glucocorticoid-induced apoptosis in CCRF CEM cells
(Bansal et al., 1991). At concentrations > 1 lLM we found it
to induce significant (> 50% by 48 h) apoptosis, as has been
reported by others (Collins et al., 1991). We found that
concentrations less than 1 ,IM for 48 h did not induce apop-
tosis. Using pulsed exposures to cycloheximide, we attempted
to determine whether there are times during the first 36 h of
dexamethasone treatment, and thereafter, during which cells
are sensitive to the effects of an inhibitor of protein synthesis.
We also wondered what effect cycloheximide would have on
changes in the c-myc protein content of the cells. There was a
profound inhibition of apoptosis when CHX was present
during the whole of first 36 h 'priming' period of exposure to
dexamethasone (Figure 3). Treatment with cycloheximide
during the period after c-myc protein had become undetec-
table (from 18 to 54 h) significantly inhibited apoptosis. Most
interestingly, incubation with CHX after the initial 36 h
exposure to dexamethasone, i.e. at a time when the cells were
'primed' for apoptosis, had no effect on the amount of
apoptosis observed at 54 h. It should be noted that during
this cycloheximide-insensitive period, there was a continued
requirement for dexamethasone (see Figure 2).
CHX treatment for the first 12 h, in the presence or
absence of dexamethasone, completely inhibited cell growth,
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with no increase in cell numbers, and an immediate (<1 h)
loss of c-myc protein was observed. This did not induce
apoptosis. First, this result allows us to confirm that this low
concentration of cycloheximide effectively inhibits protein
synthesis. Secondly, the immediate loss of c-myc protein, in
the presence or absence of dexamethasone, was not by itself
sufficient to induce apoptosis in CEM C7A cells. This will be
discussed below. Western blotting for the c-myc protein after
the removal of cycloheximide showed that the protein reap-
peared by 2h and was clearly superinduced under these
conditions by 4h (Figure 4).
Kinetics ofthe loss ofa 'memory' ofdexamethasone exposure:
comparison with re-expression ofc-mycprotein
To determine whether the events which had occurred during
the first 36 h of dexamethasone exposure, which had not
actually allowed the cells to engage in apoptosis but had
'primed' the cells (see above), were rapidly reversed, or were
retained as a 'memory' of drug exposure, clone C7A cells
were exposed to dexamethasone for 36 h (the 'priming'
period) and then washed free of drug. A second period of
18 h exposure to dexamethasone (i.e. 54 h exposure in total)
was imposed after drug-free periods ranging from zero to
48 h. Normally, 36 h plus 18 h of continuous dexamethasone
treatment induced 60% apoptosis (Figure 2). The ability of
the cells to undergo apoptosis declined as the period of
drug-free exposure after 'priming' was extended (Figure 5a).
Thus, the dexamethasone-treated cells lost the 'memory' of
their initial 36 h exposure to dexamethasone. We were partic-
ularly interested in the kinetics of the reappearance of the
c-myc protein in comparison with this time-dependent fall in
the susceptibility of the cells to apoptosis as memory of the
'priming' events was lost. Figure 5b shows that c-myc protein
was not detectable by Western blotting until 24 h, by which
time >50% the total cell population had already- become
resistant to the induction of apoptosis on readdition of dex-
amethasone. Most pertinently, after 12 h of a drug-free
incubation and subsequent readdition of dexamethasone,
apoptosis had fallen from 60% to 20%, although no c-myc
protein was detectable at 12 h. Interestingly, incubation with
CHX during the drug-free period maintained some of the
sensitivity of the cells to subsequent readdition of dex-
amethasone for 18 h (Figure 5) and so inhibited the loss of
memory of the events initiated during 'priming'. This will be
discussed below.
Discussion
The kinetics of cell death of human CCRF CEM clone C7A
lymphoid cells, induced by dexamethasone, has been defined
in detail here. Although, using morphological criteria, the
cells appeared to be apoptotic with high percentages of cells
having an intact plasma membrane and features typical of
chromatin condensation (Figure la), we were unable to
obtain good evidence of one of the cardinal biochemocal
features of apoptosis, the DNA 'ladder' (Figure lb),
indicative of internucleosomal cleavage by an endonuclease.
Analysis of DNA integrity by pulsed-field electrophoresis
showed that after 48 h of dexamethasone approximately
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Figure 3 The effects of various periods of incubation with
200 nM cycloheximide (CHX) (solid bars, bottom) on the percent-
ages of apoptotic cells at 54 h during continuous treatment with
5tM dexamethasone. Top: The kinetic profile of the onset of
apoptosis. The vertical line arbitrarily divides the profile of
apoptosis into a 0-36 h 'priming' phase and an 18 h 'com-
mitment' phase (means of three experiments with s.e.m. <5%).
p62 c-myc _
C 0 2 4 6 24h
Figure 4 Western blot of the restoration, with time, of c-myc
protein content of CCRF CEM clone C7A cells after incubation
with 200 nm cycloheximide for 36 h (no DEX present in this
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Figure 5 a, Kinetic analysis of the rate of decline of apoptosis in
clone C7A cells which had been treated with 5 fiM dexamethasone
for 36 h, the dexamethasone removed by washing, and the cells
incubated for increasing periods of time (x-axis) in fresh medium
(without dexamethasone) prior to the readdition of 5SM dex-
amethasone for 18 h. This gave a total exposure time to dex-
amethasone of 54 h, at which time the numbers of apoptotic cells
were estimated by microscopy, as detailed in Materials and
methods. CHX = 200 nM CHX was added during the intervening
dexamethasone-free periods. b, Western blot analysis of the cel-
lular amount of c-mvc protein after a 36 h exposure of cells to
5 tiM dexamethasone, at which point the cells were washed free of
the drug and harvested at the times shown.
300 kbp fragments of DNA were present (Figure lc). This
disappeared with time and diffuse bands of below 50 kbp
appeared. Work by Walker et al. (1991) has shown that
dexamethasone induces the appearance of the 300 kbp
fragments in thymocytes, and it was suggested that they may
represent domains of chromatin loops becoming detached
from their anchoring points on the nuclear matrix. These
looped domains in apoptotic thymocytes then resolved into
approximately 50 kbp fragments. Clone C7A CEM cells con-
sistently formed fragments of lower molecular weight than
this and there appeared to be much non-specific DNA
cleavage. Recent work by us (Oberhammer et al., 1993) has
shown that these large DNA fragments, which are not
resolved by standard agarose gel electrophoresis, are
observed prior to and sometimes in the absence of inter-
nucleosomal fragmentation to 180-200 bp integer DNA
fragments, typical of the DNA 'ladder'. We suggest that
apoptotic cells be identified by morphological features of
chromatin condensation and that the appearance of high
molecular weight DNA fragments is a more reliable
biochemical characteristic of condensed chromatin, in con-
trast to the appearance of internucleosomal fragments. It is
interesting that such findings were made in a cell type of
haematopoietic origin, in which the typical endonucleolytic
cleavage of DNA has been considered to be the hallmark of
apoptosis.
In contrast to immature mouse thymocytes treated with
dexamethasone, in which the onset of apoptosis is rapid (c.
6 h) (Wyllie, 1980) the onset of apoptosis in clone C7A cells
did not occur until after 36 h of drug exposure (Figure 2).
During this 36 h, changes were presumably occurring that
were essential for the subsequent expression of apoptosis
since removal of dexamethasone at any time before this failed
to induce apoptosis thereafter. This was commented on
previously by Yuh & Thompson (1989). The extended period
of drug exposure, prior to the onset of changes in chromatin
that heralds the death of the cell, is we suggest similar to the
precommitment periods observed in cells induced to ter-
minally differentiate after drug treatment (Yen et al., 1984;
Yen 1985). We equate this first 36 h with a period of 'prim-
ing' (Dive & Wyllie, 1993) of the cells for the subsequent
second phase of the engagement of apoptosis. The separation
of these two phases potentially allows for a discrete dissec-
tion of the suppression or activation of gene expression, and
protein synthesis, required for apoptosis.
Evidence from transient transfection experiments, which
utilised deletion constructs of the glucocorticoid receptor,
suggests that transcriptional suppression is necessary for the
death of clone C7A cells (Nazareth et al., 1991). Indeed, Yuh
& Thompson (1989) showed an early loss of c-myc RNA in
dexamethasone-treated clone C7A cells, confirmed here at
the protein level (Figure 2c). The loss of the c-myc protein
may contribute to the loss of some essential myc-associated
transcripts necessary for cell survival. The fall in c-myc pro-
tein occurred at a time (12 h) prior to any change in the cell
cycle of the cells (>36 h) (see Results) and, while it is
generally considered that the expression of c-myc reflects the
proliferative status of the cell population (Einat et al., 1985,
Waters et al., 1991), its absence did not inhibit the continued
proliferation of dexamethasone-treated clone C7A cells for a
period which corresponded to another full cell doubling
(Figure 2b). It has recently been reported that differentiating
agents reduced synthesis of c-myc RNA to undetectable
levels in HL-60 cells, yet these cells also underwent a full
further round of-cell division (Mitchell et al., 1992; Beere et
al., 1993a). Thus, a key 'priming' event is not a change in cell
proliferation per se, driven by a fall in c-myc expression.
Indeed, conditions of the complete inhibition of cell growth
by cycloheximide, accompanied by a fall in c-myc protein
(Figure 4), inhibited cell death induced by dexamethasone
(Figure 3).
With respect to the idea that transcriptional repression,
including that of c-nltc, is essential for the onset of apop-
tosis, Figure 3 shows that cycloheximide (CHX) completely
inhibited apoptosis if it was present during the first 36 h of
dexamethasone treatment. This is strongly suggestive of a
role for new protein synthesis during the 'priming' period,
presumably after transcriptional activation by the glucocor-
ticoid, since functionally active glucocorticoid receptors are
required for the death of these cells (Harmon & Thompson,
1981). These observations suggest that activational events,
including protein synthesis, were taking place, which subse-
quently allowed the 'machinery' of cell death to be engaged
thereafter. Presumably the synthesis of new proteins,
inhibited by CHX, had followed transcriptional activation by
dexamethasone via a glucocorticoid-responsive element.
Incubation of CCRF CEM clone C7A cells with 200 nM
CHX for 36 h also rapidly (<1 h) inhibited the expression of
c-mnvc protein, an event suggested to be a critical harbinger of
dexamethasone-induced apoptosis (Thulasi et al., 1993), but
did not induce apoptosis, suggesting that events in addition
to the loss of c-myc are critical to the engagement of
apoptosis in these cells, an idea that was supported by the
observation that CHX inhibited apoptosis even after the
suppression of c-myc protein had occurred (> 18 h) (Figure
3).
Once the cells had become 'primed', during the first 36 h
of dexamethasone tretment, apoptosis then proceeded
independently of new protein synthesis, since it was CHX
insensitive (Figure 3). As the continued presence of dex-
amethasone was required for apoptosis during the period
which followed 'priming' (i.e. after 36 h) (Figure 2) transcrip-
tional suppression, mediated via a glucocorticoid-responsive
element, was presumably the dominant event occurring in
this second phase.
Cycloheximide completely inhibited cell growth (Results),
and might have prevented apoptosis because of this or, more668 A.C. WOOD et al.
subtly, by preventing progression through some discrete 'win-
dow' of the cell cycle essential for the engagement of apop-
tosis. It should be noted that after 'priming' (i.e. after 36 h of
dexamethasone) cells were moving out of cycle, with an
accumulating number in GI phase (see Results), but were not
out of cycle. Yet cycloheximide had no effect on apoptosis
during the 'post-priming' period. It is possible that by 36 h
all of the cells had passed through this 'window' of the cell
cycle, necessary for them to later engage in apoptosis, and
that cycloheximide inhibited cell death in the first 36 h by
preventing passage through such a 'window'. Such a
hypothesis awaits provision of populations of cell cycle-
synchronised cells.
Changes which occurred in the 'priming' period, requiring
protein synthesis after transcriptional activation, remained as
a 'memory' during the following 36 h (Figure 5). The partial
maintenance of this memory by CHX (Figure 5) suggests
that messenger RNAs are possibly stabilised during this time.
Analysis of the kinetics of changes in gene expression, and
other events, during the 'priming' phase together with, and
compared with, the kinetics of the decay of memory, with or
without CHX, will be helpful in delineating the temporal
hierarchy of events leading to the commitment to death of a
cell. We plan to tackle this by a subtractive hybridisation
approach (Brady et al., 1991). It has already been com-
mented upon that the loss of c-myc protein from CEM clone
C7A cells was not an event associated with full commitment
to apoptosis, since dexamethasone treatment had to be con-
tinued for at least another 24 h before the cells became
committed to die and removal of dexamethasone prior to this
abrogated subsequent cell death (Figure 2 and Results). This
was mirrored in the kinetics of memory decay: c-myc protein
was not detectable until 24 h after dexamethasone removal.
Thus, from the combined data of Figures 2, 3 and 5 we
suggest that it is probable that an accumulation of events
before and after the suppression of c-myc expression is
required before cells can become committed to die. That
events before the loss of c-myc expression may be essential
was suggested by the observation that as the memory of
exposure to dexamethasone decayed (Figure 5) cells became
refractive to dexamethasone-induced apoptosis before re-
expression of detectable levels of c-myc protein. Thulasi et al.
(1993) recently reported that transient transfection of these
cells with either inducible or constitutively expressed c-myc-
containing constructs inhibited dexamethasone-induced cell
death. While this supports the idea that c-myc suppression is
involved in the apoptosis of these cells, our data suggest that
it is certainly not sufficient for commitment of clone C7A
cells to an apoptotic death.
Recent work in Rat-I fibroblasts has shown that artefac-
tually deregulated expression of c-myc also predisposes the
cells to die by apoptosis when they are grown under condi-
tions limiting to proliferation and survival (Evan et al.,
1992). Analogous findings in myeloid and T cells have been
reported (Askew et al., 1991; Shi et al., 1992). Even et al.
(1992) have suggested that, in addition to the role ofc-myc in
regulating cell proliferation, its capability to induce apoptosis
may act as a safeguard if cell proliferation occurs
independently of the appropriate growth factor signals. This
idea presumes that truly deregulated expression does take
place under these conditions. In support of this, earlier
studies by Wyllie et al. (1987) had shown that apoptotic rates
in transplanted fibroblasts were greater after transfection
with the c-myc gene and the ease of induction of apoptosis in
a number of different cell lines after drug treatment appeared
to correlate with their expression of the c-myc gene (Bertrand
et al., 1991). However, CCRF CEM clone C7A cells do not
appear to conform to this model since c-myc protein levels
fell prior to the onset of apoptosis with no evidence of a rise
before the onset of apoptosis. We have also recently shown
that HL-60 cells, which have an amplified c-myc gene, down-
regulate both c-myc RNA and protein prior to apoptosis
(Beere et al., 1993b).
The kinetics of the induction of cell death, the formation
of a 'memory' of exposure to dexamethasone and the kinetics
of decay of this memory, modified by CHX treatment, as
described here, promote the CCRF CEM clone C7A model
as being valuable for further studies of the genetic changes
that are required to bring about drug-induced cell death.
Careful comparisons of the kinetics of dexamethasone-
induced cell death, and the associated changes in gene expres-
sion, with those ofcell death induced by agents with different
targets within the cell should allow the determination of the
generality of the events which are necessary for the induction
of cell death. Knowing these may promote strategies for the
induction of cell death in chemoresistant tumours (Hickman,
1992).
Alan Wood was supported by a joint studentship from the Science
and Engineering Research Council and Zeneca Pharmaceuticals;
Catherine Waters was supported by the Wellcome Trust and John
Hickman was supported by Program Grant SP 2115 from the Cancer
Research Campaign. We thank Gerard Evan for antibody and
Caroline Dive for criticism of the manuscript.
References
ASKEW, D.S., ASHMUN, R.A., SIMMONS, B.C. & CLEVELAND, J.L.
(1991). Constitutive c-myc expression in an IL-3-dependent
myeloid cell line suppresses cell cycle arrest and accelerates apop-
tosis. Oncogene, 6, 1915-1922.
BANSAL, N., HOULE, A.G. & MELNYKOVYCH, G. (1991). Apoptosis:
mode of cell death induced in T cell leukemia lines by dex-
amethasone and other agents. FASEB J., 5, 211-216.
BEERE, H.M., MORIMOTO, R.I. & HICKMAN, J.A. 1993a). Investiga-
tions of mechanisms of drug-induced changes in gene expression:
N-methylformamide-induced changes in the synthesis of the M,
72,000 constitutive heat shock protein during commitment of
HL-60 cells to granulocytic differentiation. Cancer Res., 53,
3034-3039.
BEERE, H.M., HICKMAN, J.A., MORIMOTO, R.I., PARMAR, R., NEW-
BOULD, R. & WATERS, C.M. (1993b). Changes in hsc 70 and
c-myc in HL-60 cells engaging differentiation or apoptosis. Mol.
Cell Different., 1, 323-343.
BERTRAND, R., SARANG, M., JENKIN, J., KERRIGAN, D. & POM-
MIER, Y. (1991). Differential induction of secondary DNA
fragmentation by topoisomerase II inhibitors in human tumor
cell lines with amplified c-myc expression. Cancer Res., 51,
6280-6285.
BRADY, G., BARBARA, M. & ISCOVE, N.N. (1991). Amplified
representative cDNA libraries from single cells. Meth. Mol. Cell
Biol., 2, 17-25.
BROWN, D.G., SUN, X.-M. & COHEN, G.M. (1993). Dexamethasone-
induced apoptosis involves cleavage of DNA to larger fragments
prior to internucleosomal fragmentation. J. Biol. Chem., 268,
3037-3039.
COLE, M.D. (1991). Myc meets its Max. Cell, 65, 715-716.
COLLINS, R.J., HARMON, B.V., SOULVIS, T., POPE, J.H. & KERR,
J.F.R. (1991). Effects of cycloheximide on B-chronic lymphocytic
leukemia and normal lymphocytes in vitro: induction of apop-
tosis. Br. J. Cancer, 64, 518-522.
DIVE, C. & WYLLIE, A.H. (1993). Apoptosis and cancer
chemotherapy. In: Frontiers in Pharmacology: Cancer
Chemotherapy, Hickman, J.A. & Tritton, T.R. (eds), pp. 21-55.
Blackwell Scientific Publications: Oxford.
DIVE, C., GREGORY, C.D., PHIPPS, D.J., EVANS, D.L., MILNER, A.E.
& WYLLIE, A.H. (1992). Analysis and discrimination of necrosis
and apoptosis (programmed cell death) by multiparameter flow
cytometry. Biochim. Biophys. Acta, 1133, 275-285.
EILERS, M., SCHIRM, S. & BISHOP, J.M. (1991). The MYC protein
activates transcription of the a-prothymosin gene. EMBO J., 10,
133- 141.
EINAT, E., RESNITSKY, D. & KIMCHI, A. (1985). Close link between
reduction of c-myc expression by interferon and GO/GI arrest.
Nature, 313, 597-600.c-myc AND KINETICS OF DRUG-INDUCED APOPTOSIS 669
EVAN, G.I., LEWIS, G.K., RAMSEY, G. & BISHOP, J.M. (1985). Isola-
tion of monoclonal antibodies specific for human c-myc protoon-
cogene product. Mol. Cell. Biol., 5, 3610-3616.
EVAN, G.I., WYLLIE, A.H., GILBERT, C.S., LITTLEWOOD, T.D.,
LAND, H., BROOKS, M., WATERS, C.M., PENN, L.Z. & HANCOCK,
D.C. (1992). Induction of apoptosis in fibroblasts by c-myc pro-
tein. Cell, 69, 119-128.
HARMON, J.M. & THOMPSON, E.B. (1981). Isolation and charac-
terization of dexamethasone-resistant mutants from human lym-
phoid cell line CEM-7. Mol. Cell Biol., 1, 512-521.
HARMON, J.M., NORMAN, M.R., FOWLKES, B.J. & THOMPSON, E.B.
(1979). Dexamethasone induces irreversible G, arrest and death
of a human lymphoid cell line. J. Cell. Physiol., 98, 267-278.
HICKMAN, J.A. (1992). Apoptosis induced by anticancer drugs.
Cancer Metast. Rev., 11, 121-139.
MITCHELL, L.S., NEIL, R.A. & BIRNIE, G.D. (1992). Temporal rela-
tionships between induced changes in c-myc mRNA abundance,
proliferation and differentiation in HL60 cells. Differentiation, 49,
119-125.
NAZARETH, L.V., HARBOUR, D.V. & THOMPSON, E.B. (1991). Map-
ping the human glucocorticoid receptor for leukemic cell death. J.
Biol. Chem., 266, 12976-12980.
NORMAN, M.R. & THOMPSON, E.B. (1977). Characterization of a
glucocorticoid sensitive human lymphoid cell line. Cancer Res.,
37, 3875-3791.
OBERHAMMER, F., WILSON, J., DIVE, C., MORRIS, I.D., HICKMAN,
J.A., WAKELING, A.E., WALKER, P.R. & SIKORSKA, M. (1993).
Apoptotic death in epithelial cells: cleavage of DNA to 300
and/or 50 kb fragments prior to or in the absence of inter-
nucleosomal fragmentation. EMBO J., 12, 3679-3684.
OWENS, G.P. & COHEN, J.J. (1992). Identification of genes involved
in programmed cell death. Cancer Metast. Rev., 11, 149-156.
SHI, Y., GLYNN, J.M., GULBERT, L.J., COTTER, T.G., BISSONETTE,
R.P. & GREEN, D.R. (1992). Role for c-myc in activation induced
apoptotic cell deaths in T cell hybridomas. Science, 257,
212-214.
THULASI, R., HARBOUR, D.V. & THOMPSON, E.B. (1993). Suppres-
sion of c-myc is a critical step in glucocorticoid-induced human
leukemic cell lysis. J. Biol. Chem., 268, 18306-18312.
TOWBIN, H., STAEHLIN, T. & GORDON, J. (1989). Electrophoretic
transfer of proteins from polyacrylamide gels to nitrocellulose
sheets; procedures and some applications. Proc. Natl Acad. Sci.
USA, 76, 4350-4354.
WATERS, C.M., LITTLEWOOD, T.D., HANCOCK, D.C., MOORE, J.P. &
EVAN, G.I. (1991). C-myc protein expression in untransformed
fibroblasts. Oncogene, 6, 797-805.
WALKER, P.R., SMITH, C., YOUDALE, T., LEBLANC, J., WHITFIELD,
J.F. & SIKORSKA, M. (1991). Topoisomerase II-reactive
chemotherapeutic drugs induce apoptosis in thymocytes. Cancer
Res., 51, 1078-1085.
WYLLIE, A.H. (1980). Glucocorticoid-induced thymocyte apoptosis is
associated with endogenous endonuclease activation. Nature, 284,
555-556.
WYLLIE, A.H., ROSE, K.A., MORRIS, R.G., STEEL. C.M., FOSTER, E.
& SPANDIDOS, D.A. (1987). Rodent fibroblast tumours expressing
human myc and ras genes: growth metastasis and endogenous
oncogene expression. Br. J. Cancer, 56, 251-259.
YEN, A. (1985). Control of HL-60 myeloid differentiation. E.xp. Cell
Res., 156, 198-212.
YEN, A., REECE, S.A. & ALBRIGHT, K.L. (1984). Dependence of
HL60 myeloid cell differentiation oncontinuous and split retinoic
acid exposures; precommitment memory associated with altered
nuclear structure. J. Cell Physiol., 118, 277-286.
YUH, Y.-S. & THOMPSON, E.B. (1989). Glucocorticoid effect on
oncogene/growth gene expression in human T lymphoblastic
leukemic cell line CCRF-CEM. J. Biol. Chem., 264,
10904-10910.